Vanda Pharmaceuticals Receives Revised Acquisition Proposal from Future Pak

Vanda Pharmaceuticals Receives Revised Acquisition Proposal from Future Pak

Vanda Pharmaceuticals receives a revised acquisition proposal from Future Pak, LLC. Read more about the potential $8.50-$9.00 per share deal and its implications for shareholders.

Washington, D.C.: Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has confirmed the receipt of a revised unsolicited proposal from Future Pak, LLC (FP) to acquire Vanda at a price range of $8.50 to $9.00 per share in cash, plus specific Contingent Value Rights (CVRs).

Board Review Underway

Adhering to its fiduciary duties, Vanda’s Board of Directors will meticulously review and evaluate FP’s revised non-binding proposal.

The evaluation will be conducted in consultation with the company’s financial and legal advisors to determine the best action for Vanda and its shareholders.

Vanda has stated that there will be further comments on the proposal once the Board completes its review.

Currently, shareholders do not need to take any action.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals is a global biopharmaceutical company committed to developing and commercializing innovative therapies that address unmet medical needs and improve patient lives. For more information, visit their website or follow them on social media at X @vandapharma.

CompanyProposal Details
Future Pak, LLC$8.50-$9.00 per share + CVRs
Vanda Pharmaceuticals Inc.Board evaluating proposal

Cautionary Note Regarding Forward-Looking Statements

Various statements in this press release, including those regarding the Board’s intention to review FP’s proposal, are “forward-looking” under securities laws.

These statements, excluding historical facts, involve risks, uncertainties, and changes in circumstances.

Therefore, there is no assurance that Vanda’s anticipated results or developments will be realized.

Forward-looking statements are based on current expectations and assumptions.

They should be evaluated with the risk factors outlined in Vanda’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the U.S. Securities and Exchange Commission, available at

Vanda cautions investors not to rely heavily on forward-looking statements, which are qualified by cautionary statements.

Vanda undertakes no obligation to update any forward-looking statements publicly except as required by law.

Vanda Corporate Contact:

  • Kevin Moran
  • Senior Vice President, Chief Financial Officer, and Treasurer
  • Vanda Pharmaceuticals Inc.
  • 202-734-3400
  • [email protected]


The revised acquisition proposal from Future Pak, LLC marks a significant development for Vanda Pharmaceuticals. As the Board conducts its review, shareholders, and stakeholders, await further updates on this potential transaction.

Stay tuned for more information as the situation unfolds.

Post's Author

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top